Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Apr;117(8):1756–1760. doi: 10.1111/j.1476-5381.1996.tb15350.x

Protection of the aged substantia nigra of the rat against oxidative damage by (-)-deprenyl.

C P de la Cruz 1, E Revilla 1, V Steffen 1, J A Rodríguez-Gómez 1, J Cano 1, A Machado 1
PMCID: PMC1909550  PMID: 8732287

Abstract

1. We have studied the effect of (-)-deprenyl on the oxidative damage that the rat substantia nigra suffers during aging. 2. (-)-Deprenyl (2 mg kg-1, three times a week) administered for two months, beginning at 22 months of age, produced a significant increase in tyrosine hydroxylase (TH) activity (2.67 +/- 0.40 and 3.64 +/- 0.38 nmol mg-1 protein h-1 in untreated aged rats and treated aged rats respectively, P < 0.05) and in TH amount (0.072 +/- 0.012 and 0.128 +/- 0.38 absorbance 405 nm in untreated aged and treated aged rats respectively, P < 0.05). 3. The proteins of aged rat substantia nigra showed a significant decrease of carbonyl groups in treated animals compared with saline-injected control rats (136.2 +/- 21.8 and 71.5 +/- 13.2 c.p.m. microgram-1 protein in untreated aged and treated aged rats respectively, P < 0.05). 4. The carbonyl groups measured in TH enzyme showed a statistically significant decrease (42.3%) after (-)-deprenyl treatment (471.4 +/- 73.0 and 271.9 +/- 50.00 c.p.m. in untreated aged and treated aged rats respectively, P < 0.001). 5. All these results suggest that oxidative damage produced during aging is prevented by (-)-deprenyl treatment and could explain the effect of this drug in Parkinson's disease (PD) and other degenerative diseases such as Alzheimer's disease.

Full text

PDF
1756

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agnati L. F., Fuxe K., Benfenati F., Toffano G., Cimino M., Battistini N., Calza L., Merlo Pich E. Studies on aging processes. Acta Physiol Scand Suppl. 1984;532:45–61. [PubMed] [Google Scholar]
  2. Ahn B., Rhee S. G., Stadtman E. R. Use of fluorescein hydrazide and fluorescein thiosemicarbazide reagents for the fluorometric determination of protein carbonyl groups and for the detection of oxidized protein on polyacrylamide gels. Anal Biochem. 1987 Mar;161(2):245–257. doi: 10.1016/0003-2697(87)90448-9. [DOI] [PubMed] [Google Scholar]
  3. Biagini G., Zoli M., Fuxe K., Agnati L. F. L-deprenyl increases GFAP immunoreactivity selectively in activated astrocytes in rat brain. Neuroreport. 1993 Jul;4(7):955–958. doi: 10.1097/00001756-199307000-00030. [DOI] [PubMed] [Google Scholar]
  4. Birkmayer W., Knoll J., Riederer P., Youdim M. B., Hars V., Marton J. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm. 1985;64(2):113–127. doi: 10.1007/BF01245973. [DOI] [PubMed] [Google Scholar]
  5. Brandeis R., Sapir M., Kapon Y., Borelli G., Cadel S., Valsecchi B. Improvement of cognitive function by MAO-B inhibitor L-deprenyl in aged rats. Pharmacol Biochem Behav. 1991 Jun;39(2):297–304. doi: 10.1016/0091-3057(91)90183-3. [DOI] [PubMed] [Google Scholar]
  6. Carrillo M. C., Kitani K., Kanai S., Sato Y., Miyasaka K., Ivy G. O. The effect of a long term (6 months) treatment with (-)deprenyl on antioxidant enzyme activities in selective brain regions in old female Fischer 344 rats. Biochem Pharmacol. 1994 Apr 20;47(8):1333–1338. doi: 10.1016/0006-2952(94)90331-x. [DOI] [PubMed] [Google Scholar]
  7. Castaño A., Cano J., Machado A. Low selenium diet affects monoamine turnover differentially in substantia nigra and striatum. J Neurochem. 1993 Oct;61(4):1302–1307. doi: 10.1111/j.1471-4159.1993.tb13622.x. [DOI] [PubMed] [Google Scholar]
  8. Cesura A. M., Pletscher A. The new generation of monoamine oxidase inhibitors. Prog Drug Res. 1992;38:171–297. doi: 10.1007/978-3-0348-7141-9_3. [DOI] [PubMed] [Google Scholar]
  9. Cohen G., Spina M. B. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol. 1989 Nov;26(5):689–690. doi: 10.1002/ana.410260518. [DOI] [PubMed] [Google Scholar]
  10. De La Cruz C. P., Revilla E., Venero J. L., Ayala A., Cano J., Machado A. Oxidative inactivation of tyrosine hydroxylase in substantia nigra of aged rat. Free Radic Biol Med. 1996;20(1):53–61. doi: 10.1016/0891-5849(95)02025-x. [DOI] [PubMed] [Google Scholar]
  11. Harman D. The aging process. Proc Natl Acad Sci U S A. 1981 Nov;78(11):7124–7128. doi: 10.1073/pnas.78.11.7124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Heinonen E. H., Rinne U. K. Selegiline in the treatment of Parkinson's disease. Acta Neurol Scand Suppl. 1989;126:103–111. doi: 10.1111/j.1600-0404.1989.tb01789.x. [DOI] [PubMed] [Google Scholar]
  13. Heinonen E. H., Savijärvi M., Kotila M., Hajba A., Scheinin M. Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease. J Neural Transm Park Dis Dement Sect. 1993;5(3):193–202. doi: 10.1007/BF02257674. [DOI] [PubMed] [Google Scholar]
  14. Ingram D. K., Wiener H. L., Chachich M. E., Long J. M., Hengemihle J., Gupta M. Chronic treatment of aged mice with L-deprenyl produces marked striatal MAO-B inhibition but no beneficial effects on survival, motor performance, or nigral lipofuscin accumulation. Neurobiol Aging. 1993 Sep-Oct;14(5):431–440. doi: 10.1016/0197-4580(93)90101-g. [DOI] [PubMed] [Google Scholar]
  15. Kitani K., Kanai S., Sato Y., Ohta M., Ivy G. O., Carrillo M. C. Chronic treatment of (-)deprenyl prolongs the life span of male Fischer 344 rats. Further evidence. Life Sci. 1993;52(3):281–288. doi: 10.1016/0024-3205(93)90219-s. [DOI] [PubMed] [Google Scholar]
  16. Knoll J. Nigrostriatal dopaminergic activity, deprenyl treatment, and longevity. Adv Neurol. 1990;53:425–429. [PubMed] [Google Scholar]
  17. Knoll J. The pharmacological basis of the beneficial effects of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases. J Neural Transm Suppl. 1993;40:69–91. [PubMed] [Google Scholar]
  18. Knoll J. The possible mechanisms of action of (-)deprenyl in Parkinson's disease. J Neural Transm. 1978;43(3-4):177–198. doi: 10.1007/BF01246955. [DOI] [PubMed] [Google Scholar]
  19. Knoll J., Tóth V., Kummert M., Sugár J. (-)deprenyl and (-)parafluorodeprenyl-treatment prevents age-related pigment changes in the substantia nigra. A TV-image analysis of neuromelanin. Mech Ageing Dev. 1992 Apr;63(2):157–163. doi: 10.1016/0047-6374(92)90061-h. [DOI] [PubMed] [Google Scholar]
  20. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  21. Lamour Y., Dutar P., Jobert A. Septo-hippocampal neurons: altered properties in the aged rat. Brain Res. 1987 Jul 28;416(2):277–282. doi: 10.1016/0006-8993(87)90907-3. [DOI] [PubMed] [Google Scholar]
  22. Lenz A. G., Costabel U., Shaltiel S., Levine R. L. Determination of carbonyl groups in oxidatively modified proteins by reduction with tritiated sodium borohydride. Anal Biochem. 1989 Mar;177(2):419–425. doi: 10.1016/0003-2697(89)90077-8. [DOI] [PubMed] [Google Scholar]
  23. Li X. M., Qi J., Juorio A. V., Boulton A. A. Reduction in glial fibrillary acidic protein mRNA abundance induced by (-)-deprenyl and other monoamine oxidase B inhibitors in C6 glioma cells. J Neurochem. 1993 Oct;61(4):1573–1576. doi: 10.1111/j.1471-4159.1993.tb13660.x. [DOI] [PubMed] [Google Scholar]
  24. Milgram N. W., Racine R. J., Nellis P., Mendonca A., Ivy G. O. Maintenance on L-deprenyl prolongs life in aged male rats. Life Sci. 1990;47(5):415–420. doi: 10.1016/0024-3205(90)90299-7. [DOI] [PubMed] [Google Scholar]
  25. Mogi M., Harada M., Kojima K., Kiuchi K., Nagatsu I., Nagatsu T. Effects of repeated systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal tyrosine hydroxylase activity in vitro and tyrosine hydroxylase content. Neurosci Lett. 1987 Sep 23;80(2):213–218. doi: 10.1016/0304-3940(87)90656-2. [DOI] [PubMed] [Google Scholar]
  26. Nakamura S., Kawamata T., Akiguchi I., Kameyama M., Nakamura N., Kimura H. Expression of monoamine oxidase B activity in astrocytes of senile plaques. Acta Neuropathol. 1990;80(4):419–425. doi: 10.1007/BF00307697. [DOI] [PubMed] [Google Scholar]
  27. Reinhard J. F., Jr, Smith G. K., Nichol C. A. A rapid and sensitive assay for tyrosine-3-monooxygenase based upon the release of 3H2O and adsorption of [3H]-tyrosine by charcoal. Life Sci. 1986 Dec 8;39(23):2185–2189. doi: 10.1016/0024-3205(86)90395-4. [DOI] [PubMed] [Google Scholar]
  28. Rinne J. O., Röyttä M., Paljärvi L., Rummukainen J., Rinne U. K. Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease. Neurology. 1991 Jun;41(6):859–861. doi: 10.1212/wnl.41.6.859. [DOI] [PubMed] [Google Scholar]
  29. Strolin Benedetti M., Dostert P. Monoamine oxidase, brain ageing and degenerative diseases. Biochem Pharmacol. 1989 Feb 15;38(4):555–561. doi: 10.1016/0006-2952(89)90198-6. [DOI] [PubMed] [Google Scholar]
  30. Tatton W. G., Greenwood C. E. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res. 1991 Dec;30(4):666–672. doi: 10.1002/jnr.490300410. [DOI] [PubMed] [Google Scholar]
  31. Tetrud J. W., Langston J. W. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science. 1989 Aug 4;245(4917):519–522. doi: 10.1126/science.2502843. [DOI] [PubMed] [Google Scholar]
  32. Vizuete M. L., Steffen V., Ayala A., Cano J., Machado A. Protective effect of deprenyl against 1-methyl-4-phenylpyridinium neurotoxicity in rat striatum. Neurosci Lett. 1993 Apr 2;152(1-2):113–116. doi: 10.1016/0304-3940(93)90496-8. [DOI] [PubMed] [Google Scholar]
  33. Vrana S. L., Vrana K. E., Koves T. R., Smith J. E., Dworkin S. I. Chronic cocaine administration increases CNS tyrosine hydroxylase enzyme activity and mRNA levels and tryptophan hydroxylase enzyme activity levels. J Neurochem. 1993 Dec;61(6):2262–2268. doi: 10.1111/j.1471-4159.1993.tb07468.x. [DOI] [PubMed] [Google Scholar]
  34. Wolf M. E., LeWitt P. A., Bannon M. J., Dragovic L. J., Kapatos G. Effect of aging on tyrosine hydroxylase protein content and the relative number of dopamine nerve terminals in human caudate. J Neurochem. 1991 Apr;56(4):1191–1200. doi: 10.1111/j.1471-4159.1991.tb11410.x. [DOI] [PubMed] [Google Scholar]
  35. Zsilla G., Földi P., Held G., Székely A. M., Knoll J. The effect of repeated doses of (-) deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline. Pol J Pharmacol Pharm. 1986 Jan-Feb;38(1):57–67. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES